New DNA test could sharpen blood cancer diagnosis

NCT ID NCT04986657

Recruiting now Knowledge-focused Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new whole genome sequencing approach called ChromoSeq for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Researchers want to see if ChromoSeq can find more genetic changes than current standard tests, and if it can be used in real-time clinical care. About 325 adults will participate, and doctors will also be surveyed about how useful the new test is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, ChromoSeq could become a more comprehensive and faster genetic test for blood cancers, helping doctors choose better treatments.
What could go wrong: This is an early feasibility study, not a treatment trial. It may show no advantage over current tests, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROMES WHOLE GENOME SEQUENCING

Contacts and locations

Locations

Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.